Published in final edited form as:

Neurobiol Aging. 2016 January ; 37: 19–25. doi:10.1016/j.neurobiolaging.2015.09.011.

Association of *APOE* with Tau-Tangle Pathology with and without β -amyloid

Jose M. Farfel, MD, PhD^{1,2,3}, Lei Yu, PhD^{3,4}, Philip L. De Jager, MD, PhD^{5,6,7}, Julie A. Schneider, MD^{2,3,4}, and David A. Bennett, MD^{1,3,4}

¹Department of Geriatrics, University of Sao Paulo Medical School, Sao Paulo, Brazil

²Department of Pathology, Rush University Medical Center, Chicago, IL, USA

³Rush Alzheimer's Disease Center, Rush University Medical Center, Chicago, IL, USA

⁴Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA

⁵Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry, Brigham and Women's Hospital, Boston, MA, USA

⁶Harvard Medical School, Boston, MA, USA

⁷Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA

Abstract

This study tested the hypothesis that the association of *APOE* with paired helical filament tau (PHFtau) tangle pathology differs in brains with and without β -amyloid. Participants were 1,056 autopsied individuals from two clinical-pathologic cohort studies of aging and Alzheimer's disease (AD), the Religious Orders Study and the Rush Memory and Aging Project. Neuropathologic measures were obtained using immunohistochemistry targeting β -amyloid and PHFtau-tangles in 8 brain regions. Linear regression was used to compare the relation of *APOE* $\epsilon 4$ and $\epsilon 2$ to PHFtau-tangle density in persons with β -amyloid relative to persons without β -amyloid. We found an interaction between *APOE* $\epsilon 4$ carriers and presence of β -amyloid ($\beta = -0.968$, $P = 0.013$) such that the associations of *APOE* $\epsilon 4$ with PHFtau-tangles was much stronger in brains with β -amyloid. Stratified analysis shows that the association of *APOE* $\epsilon 4$ with PHFtau tangles was considerably stronger among those with β -amyloid ($\beta = 0.757$, $P = 1.1 \times 10^{-15}$) compared to those without β -amyloid which was not significant ($\beta = -0.201$, $P = 0.424$). Separately, *APOE* $\epsilon 2$ was associated with fewer tangles in brains with β -amyloid ($\beta = -0.425$, $P = 7.6 \times 10^{-4}$) compared to those without β -amyloid which was not significant ($\beta = -0.102$, $P = 0.506$). Thus, the presence of *APOE* $\epsilon 4$ and $\epsilon 2$ alleles was not associated with PHFtau tangles in the absence of β -amyloid. The data

Corresponding author: Jose M. Farfel, MD, PhD, Address: Faculdade de Medicina da Universidade de Sao Paulo, Av. Dr. Arnaldo 455, sala 1353, Sao Paulo, SP, Brasil, CEP: 01246-903, Tel: 55 11 99353-5107; Fax: 55 11 3082-4973, farfel@usp.br.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosure statement

The authors have no conflicts of interest to disclosure in relation to this study.

provide additional evidence that PHFtau-tangles in the absence of β -amyloid may reflect a pathologic process distinct from AD.

1. Introduction

The criteria for the neuropathologic diagnosis of Alzheimer's disease (AD) recently published by the National Institute on Aging-Alzheimer's Association differs from previous consensus statements (Hyman, et al., 2012). A major change is the requirement of β -amyloid deposits for the neuropathologic diagnosis of AD, in addition to neocortical neuritic plaques and neurofibrillary tangles (NFT). The requirement for β -amyloid deposits also differs from another model of pathologic AD which suggests that the appearance of NFT in the entorhinal cortex and hippocampus is the earliest neuropathologic manifestation of AD regardless of the presence of β -amyloid (Braak and Braak, 1991, Braak and Braak, 1995). Recent papers referred to the condition of tangles in the absence of amyloid as "Primary age-related tauopathy" (PART) (Crary, et al., 2014, Jellinger, et al., 2015). Thus, the extent to which tangle pathology in the absence of β -amyloid represents AD or a separate process remains controversial.

The apolipoprotein E (*APOE*) polymorphism is the most robust genetic risk factor for AD dementia (Corder, et al., 1993, Farrer, et al., 1997). Substantial evidence suggests that *APOE* affects clinical AD in large part through β -amyloid metabolism and triggers a cascade of events that ultimately results in NFT formation or propagation and cognitive impairment (Polvikoski, et al., 1995, Royall, et al., 2012, Schmechel, et al., 1993). The β -amyloid cascade hypothesis provides a biological background that can explain in part the relationship between *APOE*, β -amyloid, and NFT (Jack, et al., 2010). This raises the possibility that NFT in the absence of β -amyloid represents a pathologic process distinct from AD. In prior studies we found that β -amyloid mediated the association of *APOE* with paired helical filaments tau (PHFtau) and subsequent cognitive decline and clinical AD (Yu, et al., 2014). We also reported separate effects of age on mesial temporal lobe tangles consistent with a 2-process model of mesial temporal lobe tangles, the site of most tangles in the absence of β -amyloid (Mungas, et al., 2014). In this paper we extend our prior work by explicitly examining the association of *APOE* ϵ 4 and ϵ 2 with tangles in persons with and without β -amyloid. Finding robust associations of *APOE* with tangles in persons with β -amyloid but not in those without β -amyloid would provide additional evidence that tangles in the absence of β -amyloid represent a process distinct from AD.

2. Methods

2.1 Participants

Participants came from the Religious Orders Study (ROS) and the Rush Memory and Aging Project (MAP), both are community-based, clinical-pathologic cohort studies investigating AD and other chronic conditions of aging. Participants signed consent for annual clinical evaluations and an Anatomic Gift Act agreeing to brain donation at the time of death. Both studies enroll individuals free of known dementia. They were approved by the Institutional Review Board of Rush University Medical Center. ROS, started in 1994, enrolls older

Catholic religious clergy across the United States. MAP, started in 1997, enrolls older residents from retirement facilities and senior and subsidized housing in the Chicago metropolitan area. The follow-up rate exceeds 90% and the autopsy rate exceeds 85%. More detailed information on study design and pathologic data collection of both ROS and MAP can be found in previous publications (Bennett, et al., 2012a, Bennett, et al., 2012b).

At time of this analysis, 1,385 of 3,043 participants enrolled had died. Of the deceased, 1,373 remained in the study and 1,198 (87.3%) were autopsied. Of these, the post-mortem assessment was complete for 1,092 persons and *APOE* genotype was available on 1,056 (96.7%). The average age at death was 88.2 years (standard deviation of 6.6 years, range 65.9 to 108.3 years); and 677 (64.1%) were female. ROS and MAP cohorts are convenience samples and death is a form of informative censoring. We and others have reported that dementia is strongly associated with risk of death and thus the deceased group is enriched with persons with dementia and more neuropathologic burden. (Aguero-Torres, et al., 1999, James, et al., 2014, Rait, et al., 2010, Tschanz, et al., 2004). In order to investigate a possible bias resulting from an association between PART and mortality we explored the distribution of PART in a subset of persons enrolled early in the study and compared to the distribution of PART in the entire cohort. Among the 201 persons enrolled in the Religious Orders Study from 1994- to 1997 aged 80 and above at enrollment, 196 (98%) are deceased and 181 (90%) autopsied. Among this subset, the distribution of PART (13.2%) is similar to what is seen in the entire cohort (14.4%) suggesting that PART is not likely to be associated with selective mortality relative to other pathologies.

2.2 *APOE* Genotyping

DNA was extracted from white blood cells collected from participants or frozen brain tissue after death. *APOE* genotyping was performed by sequencing the codon 112 and codon 158 of exon 4 of the *APOE* gene (Boyle, et al., 2010). Individuals with at least one copy of the $\epsilon 4$ were considered as $\epsilon 4$ carriers. Individuals with at least one copy of the $\epsilon 2$ were considered as $\epsilon 2$ carriers. Thus, in these analyses, $\epsilon 2/\epsilon 4$ were used in both sets of models.

2.3 Neuropathology procedures

Brain removal and processing followed a standard protocol. One hemisphere was cut coronally into 1-cm slabs and fixed in 4% paraformaldehyde. β -amyloid deposits and PHF-tau tangles were assessed in 20 μ m sections. Immunohistochemistry and computer-assisted image analysis were used for β -amyloid (10D5, 1:600; Elan Pharmaceuticals, San Francisco, CA; 6F/3D, 1:50; DAKO North America Inc., Carpinteria, CA or 4G8, 1:9000 Covance Labs, Madison, WI) and stereology was used for PHFtau tangles (AT8, 1:2000; ThermoScientific, Waltham, MA) across eight different brain regions including the entorhinal cortex, the hippocampus at CA1, superior frontal cortex (Brodmann area [BA] 6/8), mid frontal cortex (BA 46/9), inferior temporal cortex (BA 20), angular gyrus cortex (BA 39/40), cingulate gyrus (BA 32/33) and calcarine cortex (BA 17). β -amyloid load and the density of PHFtau tangle density was obtained by averaging the mean percentage area per region, across all regions as previously reported (Bennett, et al., 2004). The absence of β -amyloid was characterized by a β -amyloid load of zero in all the eight immunostained sections. Neocortical type Lewy bodies (LB) were identified by alpha-synuclein positive

LB (LB509, 1:100; Invitrogen/Zymed, Carlsbad, CA or pSyn, 1:20000; Wako Chemicals, Richmond, VA) in one or more neocortical regions (midfrontal, middle temporal and inferior parietal) (Schneider, et al., 2012). Neuritic plaques (NP) and neurofibrillary tangles (NFT) were identified with modified Bielschowsky stain in 6µm sections in five different regions (entorhinal cortex, hippocampus at CA1, midfrontal cortex, middle temporal gyrus and inferior parietal cortex). CERAD criteria assessed NP burden and a Braak staging assessed the distribution and severity of NFT pathology. (Braak and Braak, 1991, Mirra, et al., 1991) The diagnosis of pathologic AD was based on the National Institute on Aging (NIA)–Reagan criteria.(1997). Macroscopic infarcts were recorded from fixed slabs and confirmed by histology. Microscopic infarcts were documented in at least 9 different sections stained with hematoxylin and eosin as previously reported (Schneider, et al., 2005). Severe neuronal cell loss and gliosis in the hippocampus on H&E was identified as hippocampal sclerosis (Nag, et al., 2015).

2.4 Other variables

Age was calculated from birth data and date of death. Sex was self-reported. We used the Mini-Mental State Examination (MMSE) score proximate to death (Bennett, et al., 2012a, Bennett, et al., 2012b, Folstein, et al., 1975).

2.5 Statistical analysis

First, we examined the frequencies of *APOE* ε4 and ε2 in three groups: those without β-amyloid and without pathologic diagnosis of AD based on NIA-Reagan criteria, presence of β-amyloid but without pathologic AD, and a group with β-amyloid deposits and with pathologic AD. Next, we examined differences in the association of *APOE* ε4 with PHFtau-tangle density in persons with and without β-amyloid. To do so, we fit a linear regression model with an interaction term between *APOE* ε4 and β-amyloid status, adjusted for age and sex. Because the variances of PHFtau tangle distribution differed between those with and without β-amyloid and this might influence the model estimation, we also conducted stratified analyses regressing *APOE* ε4 status on PHFtau tangles in persons with and without β-amyloid. Similar analyses were carried out for *APOE* ε2 genotype. Additional analyses controlled for common comorbid brain pathology including neocortical Lewy bodies, macro and microscopic infarcts and hippocampal sclerosis. In order to examine the possible confounding effect of the temporospatial differences in β-amyloid and PHFtau tangle distributions on disease severity we repeated the analyses controlling for the MMSE. Searching for possible differences in the association of *APOE* and PHFtau tangles in participants with low β-amyloid burden, we also conducted stratified analyses regressing *APOE* ε4 status on PHFtau tangles for each of three groups: without β-amyloid and without pathologic AD, presence of β-amyloid but without pathologic AD, and presence of β-amyloid and pathologic AD, adjusted for age and sex. We conducted the same analyses for *APOE* ε2 genotype. In order to investigate whether our results differ by brain regions, we repeated the analysis by examining mesial temporal and neocortical PHFtau-tangle pathologies separately.

The measures of PHFtau-tangle density were right skewed; we therefore applied square root transformation prior to the analyses. A nominal threshold of $p < 0.05$ was used to determine

significance. Analyses were performed using SAS/STAT software, version 9.3 (SAS Institute Inc. Cary, NC, USA).

3. Results

Demographic and neuropathologic characteristics of participants by β -amyloid and *APOE* $\epsilon 4$ status are shown in Table 1. *APOE* $\epsilon 4$ was present in 29.5% of persons with β -amyloid and only 7.2% of persons without β -amyloid (Chi-square=33.4, degrees of freedom=1, $P=7.7\times 10^{-9}$). The density of both neocortical and mesial temporal tangles was considerably higher in those with β -amyloid, when compared to those without β -amyloid ($P<0.001$ for both neocortical tangles and mesial temporal tangles). Table 2 shows the characteristics of participants by β -amyloid and *APOE* $\epsilon 2$ status. *APOE* $\epsilon 2$ was present in 25.7% of persons without β -amyloid and only 13.7% of persons with β -amyloid (Chi-square=14.2, degrees of freedom=1, $P=0.0002$).

The association of *APOE* $\epsilon 4$ with PHFtau tangle density was first examined in a linear regression model with an interaction term between *APOE* $\epsilon 4$ status and the presence of β -amyloid, adjusting for age and sex (Table 3). In this model, the term for *APOE* $\epsilon 4$ refers to the association of the $\epsilon 4$ allele with tangle density in persons with β -amyloid; and the interaction term compares the $\epsilon 4$ association among persons without β -amyloid relative to the reference group of persons with β -amyloid. The estimate was negative and the interaction was significant ($P=0.013$), suggesting that the association of the $\epsilon 4$ genotype with tangle density was lower among persons without β -amyloid. We next performed separate regression analysis for persons with ($N=904$) and without β -amyloid ($N=152$). In persons with β -amyloid, *APOE* $\epsilon 4$ was strongly associated with a higher burden of PHFtau tangles ($\beta=0.757$, $P=1.1\times 10^{-15}$). By contrast, we did not find an association among persons without β -amyloid ($\beta=-0.201$, $P=0.424$). Assuming the effect size of *APOE* $\epsilon 4$ were similar to the group with β -amyloid, our current sample size in the group without β -amyloid ($N=152$) would be sufficient to detect such an effect with 80% power at alpha level of 0.05. The differences in burdens of tangle pathology by *APOE* and β -amyloid status are illustrated in Figure 1. We repeated the analyses controlling for macro and microscopic infarctions, cortical Lewy bodies, and hippocampal sclerosis and the findings were essentially unchanged (data not shown). Additional stratified analyses controlled for MMSE proximate to death. The findings were essentially the same. *APOE* $\epsilon 4$ remained strongly associated with a higher burden of PHFtau tangles in persons with β -amyloid ($\beta=0.455$, $P=7.6\times 10^{-8}$), but not among persons without β -amyloid ($\beta=-0.198$, $P=0.431$). Similarly, *APOE* $\epsilon 2$ was still associated with fewer PHFtau tangles in persons with β -amyloid ($\beta=-0.300$, $P=6.2\times 10^{-3}$) but not in persons without β -amyloid ($\beta=-0.105$, $P=0.495$).

The associations of *APOE* $\epsilon 4$ with both mesial temporal tangle density and neocortical tangle density were, in general, consistent with the finding for tangle density averaged across brain regions. The $\epsilon 4$ by β -amyloid interaction was attenuated and not significant for mesial temporal tangles ($P=0.134$) and marginally significant for neocortical tangles ($P=0.050$). However, the results from stratified analyses (Tables S1 and S2) show that the association of *APOE* $\epsilon 4$ with mesial temporal tangle pathology was highly significant in persons with β -amyloid ($\beta=0.874$, $P=2.7\times 10^{-11}$) but not significant in those without β -

amyloid ($\beta=-0.026$, $P=0.963$). Similarly, the neocortical tangle density was highly significant among $\epsilon 4$ carriers in persons with β -amyloid ($\beta=0.771$, $P=2.7\times 10^{-15}$), and not significant in persons without β -amyloid ($\beta=0.009$, $P=0.926$). Next, we examined the association of *APOE* $\epsilon 2$ with tangle pathology by β -amyloid status. Our first model included an interaction term between *APOE* $\epsilon 2$ and β -amyloid status (Table 4). In this model, the term for *APOE* $\epsilon 2$ refers to the association of the $\epsilon 2$ allele with tangle density in persons with β -amyloid; and the interaction term compares the $\epsilon 2$ association among persons without β -amyloid relative to the reference group of persons with β -amyloid. The $\epsilon 2$ by β -amyloid interaction was not significant ($P=0.264$). However, the results from stratified models suggest that the magnitude of the $\epsilon 2$ association is likely to differ among persons with and without β -amyloid. In these models, *APOE* $\epsilon 2$ was associated with fewer PHFtau tangles in persons with β -amyloid ($\beta=-0.425$, $P=7.6\times 10^{-4}$). By contrast, we did not find an association in persons without β -amyloid ($\beta=-0.102$, $P=0.506$). Power calculation suggests that it would require a sample size $\sim 4,400$ to detect $\epsilon 2$ by β -amyloid interaction at a nominal α level of 0.05. Further adjustment for macro and microscopic infarctions, cortical Lewy bodies, and hippocampal sclerosis did not change the results (data not shown).

Similar results were found in separate analyses of $\epsilon 2$ on mesial temporal tangles and neocortical tangles. Briefly, we did not find significant $\epsilon 2$ by β -amyloid interactions on either tangle pathology. However, stratified regression models show that in persons with β -amyloid, the $\epsilon 2$ carriers had lower mesial temporal ($\beta=-0.479$, $P=0.005$) and neocortical tangle densities ($\beta=-0.551$, $P=2.3\times 10^{-5}$). By contrast, both associations were greatly attenuated and were not significant in persons without β -amyloid (Tables S1 and S2).

Finally, we conducted stratified analyses regressing *APOE* $\epsilon 4$ status on PHFtau tangles in three groups: without β -amyloid and without pathologic AD ($N=152$), presence of β -amyloid but without pathologic AD ($N=245$), and presence of β -amyloid and pathologic AD ($N=659$) (Table 5). We observe that *APOE* $\epsilon 4$ was strongly associated with a higher burden of PHFtau tangles in the group with pathologic AD ($\beta=0.592$, $P=5.8\times 10^{-8}$). The association was significant but much weaker in the group with β -amyloid but without pathologic AD ($\beta=0.266$, $P=0.032$). Finally, as before, we did not find the association among persons without β -amyloid ($\beta=-0.201$, $P=0.424$). We repeated the analysis for *APOE* $\epsilon 2$ allele (Table 5), and observe significant association of *APOE* $\epsilon 2$ and PHFtau tangles only in the group with pathologic AD ($\beta=-0.536$, $P=5.9\times 10^{-4}$). Note the point estimate for the group with β -amyloid but without pathologic AD is about 70% of that for *APOE* $\epsilon 4$; thus the lack of association could be the result of a reduction of power among those with this allele.

4. Discussion

In this study, we identified marked differences in the association between *APOE* and PHFtau tangles among persons with and without β -amyloid deposits. Specifically, we found that *APOE* $\epsilon 4$ is strongly associated with a higher density of PHFtau tangles and *APOE* $\epsilon 2$ is associated with fewer PHFtau tangles in brains with β -amyloid but not in brains without β -amyloid. The association of *APOE* $\epsilon 4$ and PHFtau tangles was also observed in the participants with low β -amyloid burden insufficient for a pathologic diagnosis of AD but not in the absence of β -amyloid suggesting that the association of *APOE* with PHFtau tangles

depends upon β -amyloid presence. Results were similar when examining mesial temporal and neocortical tangle separately. Further, they were unchanged after controlling for cognitive performance and other common neuropathologies. We are unaware of prior studies examining whether the association of *APOE* and PHFtau tangles differs by β -amyloid deposition.

Many previous studies reported associations between *APOE* and β -amyloid deposition and NFT (Nagy, et al., 1995, Ohm, et al., 1995). Post-mortem studies showed that β -amyloid levels in the brain, the load of β -amyloid and NFT's vary according to *APOE* genotype ($\epsilon 4 > \epsilon 3 > \epsilon 2$) (Bennett, et al., 2009, Nicoll, et al., 2011, Sabbagh, et al., 2013). These studies reveal a concurrent and symmetric association of *APOE* with both β -amyloid and NFT, suggesting that the association of *APOE* with NFT could be mediated by β -amyloid. Only one neuropathologic study found an association between *APOE* $\epsilon 2$ carriers and increased β -amyloid pathology. However, this study was performed in a population much older than the sample included in this and other studies suggesting that the relation between *APOE* and neuropathology may vary according to age (Berlau, et al., 2009).

Robust experimental studies in transgenic mice link *APOE* $\epsilon 4$ and $\epsilon 2$ to distinct mechanisms of β -amyloid processing and metabolism. *APOE*-E4-lipoproteins reportedly have lower binding affinity to β -amyloid and as result may be less efficient in mediating β -amyloid clearance (Castellano, et al., 2011, LaDu, et al., 1994). *APOE* E4 isoform may also be less efficient in mediating degradation of β -amyloid (Jiang, et al., 2008). *APOE* $\epsilon 2$ has been shown to be most effective in clearing β -amyloid from the brain and bloodstream and avoiding β -amyloid deposition by preventing the conversion of sustained forms of β -amyloid into pathologic oligomers (Fagan, et al., 2002, Ma, et al., 1994, Sharman, et al., 2010). By contrast, the direct effect of both *APOE* $\epsilon 4$ and $\epsilon 2$ to PHFtau pathology is less clear with few experimental studies showing that *APOE*-4 isoforms may induce fibrillary tangle-like intracellular inclusions in neurons containing phosphorylated tau (Brecht, et al., 2004, Huang, 2010).

The results of this study support the hypothesis of a 2-process model underlying PHFtau tangles in mesial temporal lobes (Crary, et al., 2014, Jellinger, et al., 2015, Mungas, et al., 2014, Nelson, et al., 2009, Royall and Palmer, 2014). The first one is the AD process characterized by the presence of β -amyloid deposits and recognized by the most recent guidelines for diagnosis of neuropathologic AD. Previous studies advocate that β -amyloid deposits are the initial AD event that triggers a cascade of events that will result in PHFtau tangles formation (Hardy and Selkoe, 2002, Jack, et al., 2011). In our study, the density of PHFtau tangles was much higher in brains with β -amyloid and in the group with β -amyloid *APOE* was very strongly associated with PHFtau tangles. Even in the subjects with low β -amyloid burden it was possible to find an association between *APOE* $\epsilon 4$ and PHFtau tangles demonstrating that the presence of a low β -amyloid load is sufficient to find an association of *APOE* with PHFtau tangles. These are all evidence in favor of the β -amyloid cascade hypothesis. The second process is the presence of PHFtau tangles, especially in mesial temporal lobes in the absence of β -amyloid. In previous studies PHFtau tangles alone had been associated with age and cognitive impairment (Jellinger and Attems, 2007, Nelson, et al., 2009, Yamada, 2003). Further, PHFtau tangles can characterize a number of conditions

other than AD including chronic traumatic encephalopathy, progressive supranuclear palsy, corticobasal degeneration, and tau mutations (Klein, et al., 2004, Nelson, et al., 2009, Yoshiyama, et al., 2005). In our study, this second process is characterized by a lower density of PHFtau tangles in mesial temporal lobes, concentrates *APOE* ϵ 2 carriers and in these subjects *APOE* is not associated with PHFtau tangles when compared to the first process.

An alternative hypothesis conflicting with the β -amyloid cascade hypothesis is that AD begins with PHFtau in mesial temporal lobe and spreads through the brain following a uniform and progressive pattern (Braak and Del Tredici, 2011). Recent animal models with transgenic mice suggest that tau pathology may be transmitted from neuron to neuron through a trans-synaptic mechanism from mesial temporal lobe to neocortical regions (Liu, et al., 2012). What might be considered a hybrid hypothesis is one in which AD begins with mesial temporal lobe tangles and the spread of tangles through the brain is augmented by β -amyloid (Jack, 2014). Further, experimental studies suggest that intraneuronal β -amyloid oligomers are associated to synaptic dysfunction, a process that may contribute to trans-synaptic tau spread and is enhanced in *APOE* ϵ 4 carriers (Koffie, et al., 2012, Sen, et al., 2012). Thus, the presence of β -amyloid could augment the spreading of PHFtau tangles. Our findings of a greater density of PHFtau tangles in persons with β -amyloid are also consistent with this model of AD.

This study has limitations. As few *APOE* ϵ 4 carriers are without β -amyloid, a much larger sample might have identified an association between *APOE* and PHFtau tangles in persons without β -amyloid. However, if there is any association between *APOE* and PHFtau tangles in persons without β -amyloid it remains much weaker than the association found in those with β -amyloid. Power calculations suggested that the sample size included in the group without β -amyloid would be sufficient to detect an association of *APOE* ϵ 4 and PHFtau tangles if the effect size were similar to the group with β -amyloid. Second, we did not determine specific associations of *APOE* to the different specific species of β -amyloid such as 42 or 40. Likewise, different tau antibodies identify slightly different subpopulations of tangles. Third, the convenience sample used in this study may limit the generalizability of our findings. Finally, the participants were much older than many other studies and it's possible that the associations vary by age.

The study also had a number of strengths. The major strengths are the large sample size from two prospective community-based studies of older persons. Both enjoyed very high clinical follow-up and autopsy rates. Further, they employed identical uniform quantitative post-mortem procedures by examiners blinded to *APOE* status.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

The authors are grateful to the staff of the Rush Alzheimer's Disease Center. This work was supported by National Institute of Aging grants: P30AG10161, RF1AG15819, R01AG17917, R01AG42210 and U01AG46152.

References

- Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. *Neurobiology of aging*. 1997; 18(4 Suppl):S1–S2. [PubMed: 9330978]
- Aguero-Torres H, Fratiglioni L, Guo Z, Viitanen M, Winblad B. Mortality from dementia in advanced age: a 5-year follow-up study of incident dementia cases. *Journal of clinical epidemiology*. 1999; 52(8):737–743. [PubMed: 10465318]
- Bennett DA, De Jager PL, Leurgans SE, Schneider JA. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. *Neurology*. 2009; 72(17):1495–1503. [PubMed: 19398704]
- Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS. Overview and findings from the religious orders study. *Current Alzheimer research*. 2012a; 9(6):628–645. [PubMed: 22471860]
- Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS. Overview and findings from the rush Memory and Aging Project. *Current Alzheimer research*. 2012b; 9(6):646–663. [PubMed: 22471867]
- Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. *Archives of neurology*. 2004; 61(3):378–384. [PubMed: 15023815]
- Berlau DJ, Corrada MM, Head E, Kawas CH. APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. *Neurology*. 2009; 72(9):829–834. [PubMed: 19255410]
- Boyle PA, Buchman AS, Wilson RS, Kelly JF, Bennett DA. The APOE epsilon4 allele is associated with incident mild cognitive impairment among community-dwelling older persons. *Neuroepidemiology*. 2010; 34(1):43–49. [PubMed: 19907191]
- Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta neuropathologica*. 1991; 82(4):239–259. [PubMed: 1759558]
- Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. *Neurobiology of aging*. 1995; 16(3):271–278. discussion 8–84. [PubMed: 7566337]
- Braak H, Del Tredici K. Alzheimer's pathogenesis: is there neuron-to-neuron propagation? *Acta neuropathologica*. 2011; 121(5):589–595. [PubMed: 21516512]
- Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee Fish J, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. *The Journal of neuroscience : the official journal of the Society for Neuroscience*. 2004; 24(10):2527–2534. [PubMed: 15014128]
- Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. *Science translational medicine*. 2011; 3(89):89ra57.
- Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science*. 1993; 261(5123):921–923. [PubMed: 8346443]
- Crary JF, Trojanowski JQ, Schneider JA, Abisambra JF, Abner EL, Alafuzoff I, Arnold SE, Attems J, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Gearing M, Grinberg LT, Hof PR, Hyman BT, Jellinger K, Jicha GA, Kovacs GG, Knopman DS, Kofler J, Kukull WA, Mackenzie IR, Masliah E, McKee A, Montine TJ, Murray ME, Neltner JH, Santa-Maria I, Seeley WW, Serrano-Pozo A, Shelanski ML, Stein T, Takao M, Thal DR, Toledo JB, Troncoso JC, Vonsattel JP, White CL 3rd, Wisniewski T, Woltjer RL, Yamada M, Nelson PT. Primary age-related tauopathy (PART): a common pathology associated with human aging. *Acta neuropathologica*. 2014; 128(6):755–766. [PubMed: 25348064]
- Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. *Neurobiology of disease*. 2002; 9(3):305–318. [PubMed: 11950276]

- Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, Myers RH, Pericak-Vance MA, Risch N, van Duijn CM. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *Jama*. 1997; 278(16):1349–1356. [PubMed: 9343467]
- Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *Journal of psychiatric research*. 1975; 12(3):189–198. [PubMed: 1202204]
- Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science*. 2002; 297(5580):353–356. [PubMed: 12130773]
- Huang Y. Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. *Trends in molecular medicine*. 2010; 16(6):287–294. [PubMed: 20537952]
- Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS, Nelson PT, Schneider JA, Thal DR, Thies B, Trojanowski JQ, Vinters HV, Montine TJ. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*. 2012; 8(1):1–13.
- Jack CR Jr. PART and SNAP. *Acta neuropathologica*. 2014; 128(6):773–6. [PubMed: 25380757]
- Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. *The Lancet Neurology*. 2010; 9(1):119–128. [PubMed: 20083042]
- Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Aisen PS, Trojanowski JQ, Shaw LM, Bernstein MA, Petersen RC, Weiner MW, Knopman DS, Alzheimer's Disease Neuroimaging, I. Evidence for ordering of Alzheimer disease biomarkers. *Archives of neurology*. 2011; 68(12):1526–1535. [PubMed: 21825215]
- James BD, Leurgans SE, Hebert LE, Scherr PA, Yaffe K, Bennett DA. Contribution of Alzheimer disease to mortality in the United States. *Neurology*. 2014; 82(12):1045–1050. [PubMed: 24598707]
- Jellinger KA, Alafuzoff I, Attems J, Beach TG, Cairns NJ, Crary JF, Dickson DW, Hof PR, Hyman BT, Jack CR Jr, Jicha GA, Knopman DS, Kovacs GG, Mackenzie IR, Masliah E, Montine TJ, Nelson PT, Schmitt F, Schneider JA, Serrano-Pozo A, Thal DR, Toledo JB, Trojanowski JQ, Troncoso JC, Vonsattel JP, Wisniewski T. PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. *Acta neuropathologica*. 2015
- Jellinger KA, Attems J. Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease. *Acta neuropathologica*. 2007; 113(2):107–117. [PubMed: 17089134]
- Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE. ApoE promotes the proteolytic degradation of Abeta. *Neuron*. 2008; 58(5):681–693. [PubMed: 18549781]
- Klein WL, Stine WB Jr, Teplow DB. Small assemblies of unmodified amyloid beta-protein are the proximate neurotoxin in Alzheimer's disease. *Neurobiology of aging*. 2004; 25(5):569–580. [PubMed: 15172732]
- Koffie RM, Hashimoto T, Tai HC, Kay KR, Serrano-Pozo A, Joyner D, Hou S, Kopeikina KJ, Frosch MP, Lee VM, Holtzman DM, Hyman BT, Spires-Jones TL. Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-beta. *Brain : a journal of neurology*. 2012; 135(Pt 7):2155–2168. [PubMed: 22637583]
- LaDu MJ, Falduto MT, Manelli AM, Reardon CA, Getz GS, Frail DE. Isoform-specific binding of apolipoprotein E to beta-amyloid. *The Journal of biological chemistry*. 1994; 269(38):23403–23406. [PubMed: 8089103]
- Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K. Trans-synaptic spread of tau pathology in vivo. *PloS one*. 2012; 7(2):e31302. [PubMed: 22312444]
- Ma J, Yee A, Brewer HB Jr, Das S, Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. *Nature*. 1994; 372(6501):92–94. [PubMed: 7969426]

- Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology*. 1991; 41(4):479–486. [PubMed: 2011243]
- Mungas D, Tractenberg R, Schneider JA, Crane PK, Bennett DA. A 2-process model for neuropathology of Alzheimer's disease. *Neurobiology of aging*. 2014; 35(2):301–308. [PubMed: 24080173]
- Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA, Schneider JA. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer's Disease. *Annals of neurology*. 2015
- Nagy Z, Esiri MM, Jobst KA, Johnston C, Litchfield S, Sim E, Smith AD. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. *Neuroscience*. 1995; 69(3):757–761. [PubMed: 8596645]
- Nelson PT, Abner EL, Schmitt FA, Kryscio RJ, Jicha GA, Santacruz K, Smith CD, Patel E, Markesbery WR. Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. *J Neuropathol Exp Neurol*. 2009; 68(7):774–784. [PubMed: 19535994]
- Nicoll JA, Savva GM, Stewart J, Matthews FE, Brayne C, Ince P, Medical Research Council Cognitive, F. Ageing S. Association between APOE genotype, neuropathology and dementia in the older population of England and Wales. *Neuropathology and applied neurobiology*. 2011; 37(3):285–294. [PubMed: 20880354]
- Ohm TG, Kirca M, Bohl J, Scharnagl H, Gross W, Marz W. Apolipoprotein E polymorphism influences not only cerebral senile plaque load but also Alzheimer-type neurofibrillary tangle formation. *Neuroscience*. 1995; 66(3):583–587. [PubMed: 7644022]
- Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto L, Halonen P, Kontula K. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. *The New England journal of medicine*. 1995; 333(19):1242–1247. [PubMed: 7566000]
- Rait G, Walters K, Bottomley C, Petersen I, Iliffe S, Nazareth I. Survival of people with clinical diagnosis of dementia in primary care: cohort study. *Bmj*. 2010; 341:c3584. [PubMed: 20688840]
- Royall DR, Palmer RF. The temporospatial evolution of neuritic plaque-related and independent tauopathies: implications for dementia staging. *Journal of Alzheimer's disease : JAD*. 2014; 40(3): 541–549. [PubMed: 24577462]
- Royall DR, Palmer RF, Petrovitch H, Ross GW, Masaki K, White LR. Modeling regional vulnerability to Alzheimer pathology. *Neurobiology of aging*. 2012; 33(8):1556–1563. [PubMed: 21803455]
- Sabbagh MN, Malek-Ahmadi M, Dugger BN, Lee K, Sue LI, Serrano G, Walker DG, Davis K, Jacobson SA, Beach TG. The influence of Apolipoprotein E genotype on regional pathology in Alzheimer's disease. *BMC neurology*. 2013; 13:44. [PubMed: 23663404]
- Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. *Proceedings of the National Academy of Sciences of the United States of America*. 1993; 90(20):9649–9653. [PubMed: 8415756]
- Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. *Brain : a journal of neurology*. 2012; 135(Pt 10):3005–3014. [PubMed: 23065790]
- Schneider JA, Bienias JL, Wilson RS, Berry-Kravis E, Evans DA, Bennett DA. The apolipoprotein E epsilon4 allele increases the odds of chronic cerebral infarction [corrected] detected at autopsy in older persons. *Stroke; a journal of cerebral circulation*. 2005; 36(5):954–959.
- Sen A, Alkon DL, Nelson TJ. Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase C epsilon. *The Journal of biological chemistry*. 2012; 287(19):15947–15958. [PubMed: 22427674]
- Sharman MJ, Morici M, Hone E, Berger T, Taddei K, Martins IJ, Lim WL, Singh S, Wenk MR, Ghiso J, Buxbaum JD, Gandy S, Martins RN. APOE genotype results in differential effects on the peripheral clearance of amyloid-beta42 in APOE knock-in and knock-out mice. *Journal of Alzheimer's disease : JAD*. 2010; 21(2):403–409. [PubMed: 20555142]

- Tschanz JT, Corcoran C, Skoog I, Khachaturian AS, Herrick J, Hayden KM, Welsh-Bohmer KA, Calvert T, Norton MC, Zandi P, Breitner JC, Cache County Study, G. Dementia: the leading predictor of death in a defined elderly population: the Cache County Study. *Neurology*. 2004; 62(7):1156–1162. [PubMed: 15079016]
- Yamada M. Senile dementia of the neurofibrillary tangle type (tangle-only dementia): neuropathological criteria and clinical guidelines for diagnosis. *Neuropathology : official journal of the Japanese Society of Neuropathology*. 2003; 23(4):311–317. [PubMed: 14719548]
- Yoshiyama Y, Uryu K, Higuchi M, Longhi L, Hoover R, Fujimoto S, McIntosh T, Lee VM, Trojanowski JQ. Enhanced neurofibrillary tangle formation, cerebral atrophy, and cognitive deficits induced by repetitive mild brain injury in a transgenic tauopathy mouse model. *Journal of neurotrauma*. 2005; 22(10):1134–1141. [PubMed: 16238489]
- Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. *Neurobiology of aging*. 2014; 35(4):819–826. [PubMed: 24199961]

Highlights

- We tested the association of *APOE* with tau-tangles in brains with and without β -amyloid
- *APOE* $\epsilon 4$ was strongly associated with PHFtau-tangles in brains with β -amyloid
- *APOE* $\epsilon 2$ was associated with fewer tangles in brains with β -amyloid
- *APOE* $\epsilon 4$ and $\epsilon 2$ were not associated with tau-tangles in the absence of β -amyloid
- Data suggests that PHFtau-tangles and no β -amyloid is a distinct pathologic process

Figure 1.
PHF-tau tangle density by *APOE* status and the presence or absence of β -amyloid.

Table 1
Demographic and neuropathologic characteristics of participants by β -amyloid and *APOE* $\epsilon 4$ status

Mean (SD) or N	Without β -amyloid and without AD		With β -amyloid but without AD		With β -amyloid and with AD	
	<i>APOE</i> $\epsilon 4$ +	<i>APOE</i> $\epsilon 4$ –	<i>APOE</i> $\epsilon 4$ +	<i>APOE</i> $\epsilon 4$ –	<i>APOE</i> $\epsilon 4$ +	<i>APOE</i> $\epsilon 4$ –
N	11 (7.2)	141 (92.8)	42 (17.1)	203 (82.9)	225 (34.1)	434 (65.9)
Age at death	87.3 (6.3)	86.0 (7.3)	85.5 (7.2)	86.7 (7.3)	87.8 (5.9)	90.3 (5.8)
Male sex	5 (45.5%)	60 (42.5%)	22 (52.4%)	79 (38.9%)	76 (33.8%)	137 (31.6%)
Mini-Mental State Exam	24.2 (5.2)	23.9 (7.5)	22.6 (9.6)	25.4 (5.7)	16.9 (10.0)	19.8 (9.3)
β -amyloid load	0	0	2.4 (2.5)	1.3 (1.8)	6.6 (4.2)	5.7 (4.2)
PHFtau tangle density	2.3 (3.9)	2.3 (2.5)	3.0 (3.5)	2.1 (2.2)	11.2 (11.2)	7.3 (6.8)
Neocortical PHFtau	0.17 (0.37)	0.17 (0.47)	0.5 (1.8)	0.2 (0.6)	6.7 (10.7)	3.3 (5.5)
Mesial Temporal PHFtau	13.8 (21.8)	9.5 (9.5)	10.8 (11.2)	8.1 (8.1)	25.6 (18.0)	20.3 (14.2)
Cortical Lewy bodies	0	11 (7.8%)	4 (9.5%)	14 (6.9%)	37 (16.4%)	54 (12.4%)
Macro infarcts	5 (45.5%)	44 (31.2%)	18 (42.9%)	69 (34.0%)	88 (39.1%)	149 (34.3%)
Micro infarcts	4 (36.4%)	37 (26.2%)	10 (23.8%)	55 (27.1%)	63 (28.0%)	134 (30.9%)
Hippocampal sclerosis	1 (10%)	5 (3.6%)	2 (5.0%)	10 (5.0%)	29 (12.9%)	36 (8.4%)

Demographic and neuropathologic characteristics of participants by β -amyloid and *APOE* $\epsilon 2$ status**Table 2**

	Without β -amyloid and without AD		With β -amyloid but without AD		With β -amyloid and with AD	
	<i>APOE</i> $\epsilon 2$ +	<i>APOE</i> $\epsilon 2$ –	<i>APOE</i> $\epsilon 2$ +	<i>APOE</i> $\epsilon 2$ –	<i>APOE</i> $\epsilon 2$ +	<i>APOE</i> $\epsilon 2$ –
N	39 (25.7)	113 (74.3)	43 (17.6)	202 (82.4)	81 (12.3)	578 (87.7)
Age at death	88.4 (8.3)	85.3 (6.7)	87.1 (7.0)	86.3 (7.3)	90.7 (5.9)	89.2 (5.9)
Male sex	11 (28.2%)	54 (47.8%)	17 (39.5%)	84 (41.6%)	25 (30.9%)	188 (32.5%)
Mini-Mental State Exam	23.0 (8.9)	24.3 (6.9)	23.5 (7.9)	25.3 (6.2)	20.7 (8.7)	18.6 (9.7)
β -amyloid load	0	0	1.0 (1.5)	1.6 (2.1)	5.2 (3.8)	6.1 (4.2)
PHFtau tangle density	2.4 (3.0)	2.3 (2.5)	2.7 (2.5)	2.2 (2.5)	5.9 (5.8)	9.0 (9.0)
Neocortical PHFtau	0.12 (0.25)	0.19 (0.51)	0.3 (1.3)	0.3 (0.8)	2.0 (4.3)	4.8 (8.1)
Mesial Temporal PHFtau	10.7 (12.0)	9.5 (10.1)	10.0 (8.3)	8.3 (8.9)	17.8 (14.7)	22.7 (15.8)
Cortical Lewy bodies	1 (2.6%)	10 (8.9%)	8 (18.6%)	10 (5.0%)	4 (4.9%)	87 (15.1%)
Macro infarcts	14 (35.9%)	35 (31.0%)	12 (27.9%)	75 (37.1%)	39 (48.2%)	198 (34.3%)
Micro infarcts	14 (35.9%)	27 (23.9%)	10 (23.3%)	55 (27.2%)	28 (34.6%)	169 (29.2%)
Hippocampal sclerosis	3 (8.1%)	3 (2.7%)	0	12 (6.1%)	8 (9.9%)	57 (9.9%)

Table 3Association of *APOE* $\epsilon 4$ status with PHFtau tangles density

Parameters	β (SE), p	β (SE), p
β -amyloid (absent)	-0.715 (0.109), <.001	-0.633 (0.114), <.001
<i>APOE</i> $\epsilon 4+$	0.702 (0.086), <.001	0.752 (0.089), <.001
β -Amyloid (absent)* <i>APOE</i> $\epsilon 4+$	-	-0.968 (0.388), 0.013

Table 3 presented β coefficient, Standard error (SE), and p value from the models without and with interaction term between $\epsilon 4$ status and the presence of β -amyloid. Both models were adjusted for age and sex.

Table 4Association of *APOE* $\epsilon 2$ status with PHFtau tangles density

Parameters	β (SE), p	β (SE), p
β -amyloid (ab0sent)	-0.837 (0.107), <.001	-0.905 (0.126), <.001
<i>APOE</i> $\epsilon 2+$	-0.362 (0.107), <.001	-0.424 (0.120), <.001
β -amyloid (absent)* <i>APOE</i> $\epsilon 2+$	-	0.291 (0.260), 0.264

Table 4 presented β coefficient, Standard error (SE), and p value from the models without and with interaction term between $\epsilon 2$ status and the presence of β -amyloid. Both models were adjusted for age and sex

Table 5

Association of *APOE* status with PHFtau tangles density, stratified by β -amyloid status

	<i>APOE</i> $\epsilon 4+$	<i>APOE</i> $\epsilon 2+$
Parameters	β (SE), <i>p</i>	β (SE), <i>p</i>
Without β -amyloid and without AD (N=152)	−0.201 (0.205), 0.423	−0.102 (0.153), 0.505
With β -amyloid but without AD (N=659)	0.266 (0.124), 0.03	−0.185 (0.122), 0.132
With β -amyloid and with AD (N=245)	0.592 (0.107), <0.001	−0.536 (0.155), <0.001

Table 5 presented β coefficient, Standard error (SE), and *p* value from four models. All the models were adjusted for age and sex.